Ocugen Non Recurring from 2010 to 2024
| OCGN Stock | USD 0.92 0.01 1.10% |
Non Recurring | First Reported 2010-12-31 | Previous Quarter 8.1 M | Current Value 8.5 M | Quarterly Volatility 4 M |
Check Ocugen financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Ocugen's main balance sheet or income statement drivers, such as Depreciation And Amortization of 582.4 K, Interest Expense of 4.2 M or Selling General Administrative of 33.6 M, as well as many indicators such as Price To Sales Ratio of 22.11, Dividend Yield of 0.0 or PTB Ratio of 3.64. Ocugen financial statements analysis is a perfect complement when working with Ocugen Valuation or Volatility modules.
Ocugen | Non Recurring |
Latest Ocugen's Non Recurring Growth Pattern
Below is the plot of the Non Recurring of Ocugen Inc over the last few years. It is Ocugen's Non Recurring historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Ocugen's overall financial position and show how it may be relating to other accounts over time.
| Non Recurring | 10 Years Trend |
|
Non Recurring |
| Timeline |
Ocugen Non Recurring Regression Statistics
| Arithmetic Mean | 3,762,833 | |
| Coefficient Of Variation | 104.98 | |
| Mean Deviation | 3,786,644 | |
| Median | 7,000,000 | |
| Standard Deviation | 3,950,408 | |
| Sample Variance | 15.6T | |
| Range | 8.8M | |
| R-Value | 0.89 | |
| Mean Square Error | 3.4T | |
| R-Squared | 0.80 | |
| Slope | 789,420 | |
| Total Sum of Squares | 218.5T |
Ocugen Non Recurring History
About Ocugen Financial Statements
Ocugen investors utilize fundamental indicators, such as Non Recurring, to predict how Ocugen Stock might perform in the future. Analyzing these trends over time helps investors make informed market timing decisions. For further insights, please visit our fundamental analysis page.
| Last Reported | Projected for Next Year | ||
| Non Recurring | 8.1 M | 8.5 M |
Check out the analysis of Ocugen Correlation against competitors. You can also try the Pair Correlation module to compare performance and examine fundamental relationship between any two equity instruments.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Ocugen. If investors know Ocugen will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Ocugen listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (0.19) | Revenue Per Share 0.018 | Quarterly Revenue Growth 1.353 | Return On Assets (0.48) | Return On Equity (1.03) |
The market value of Ocugen Inc is measured differently than its book value, which is the value of Ocugen that is recorded on the company's balance sheet. Investors also form their own opinion of Ocugen's value that differs from its market value or its book value, called intrinsic value, which is Ocugen's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Ocugen's market value can be influenced by many factors that don't directly affect Ocugen's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Ocugen's value and its price as these two are different measures arrived at by different means. Investors typically determine if Ocugen is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Ocugen's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.